You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

USH2A

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

USHer Syndrome (CRUSH) Study

Active, not recruiting
  • Usher Syndrome, Type 2A
  • +2 more
  • No intervention
  • Nijmegen, Gelderland, Netherlands
    Radboud universitair medisch centrum
Apr 28, 2022

Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Dallas, Madison, London (QR-421a, Sham-procedure)

Active, not recruiting
  • Retinitis Pigmentosa
  • +7 more
  • Dallas, Texas
  • +2 more
Apr 21, 2022

Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Canada, France, United States (QR-421a, Sham-procedure (dose

Completed
  • Retinitis Pigmentosa
  • +7 more
  • QR-421a
  • Sham-procedure (dose cohort 1&2 only)
  • Boston, Massachusetts
  • +6 more
Apr 19, 2022

Rate of Progression in USH2A-related Retinal Degeneration

Active, not recruiting
  • Usher Syndrome, Type 2A
  • Retinitis Pigmentosa 39
    • San Francisco, California
    • +15 more
    Mar 8, 2022

    Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Worldwide (Ultevursen, Sham-procedure)

    Recruiting
    • Retinitis Pigmentosa
    • +7 more
    • San Diego, California
    • +14 more
    Jul 29, 2022

    Retinitis Pigmentosa, Usher Syndrome Type 2 Trial in Canada, France, United States (RNA antisense oligonucleotide for

    Terminated
    Has Results
    • Retinitis Pigmentosa
    • Usher Syndrome Type 2
    • RNA antisense oligonucleotide for intravitreal injection
    • Boston, Massachusetts
    • +6 more
    Dec 12, 2022

    Depressive Disorder, Major, Alcoholism Trial in Seoul (Vortioxetine, Acamprosate)

    Unknown status
    • Depressive Disorder, Major
    • Alcoholism
    • Seoul, Korea, Republic of
      Hanyang USH
    Jul 30, 2020

    Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC Trial (LX2020)

    Not yet recruiting
    • Arrhythmogenic Cardiomyopathy
    • +2 more
    • LX2020
    • (no location specified)
    Oct 25, 2023

    PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) Trial in La Jolla, Philadelphia (RP-A601)

    Not yet recruiting
    • PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
    • RP-A601
    • La Jolla, California
    • +1 more
    May 22, 2023

    CYP1A2, ABCB1, CYP2C9 and Plasma Concentration of Agomelatine in

    Not yet recruiting
    • Polymorphism, Genetic
    • +5 more
      • (no location specified)
      Nov 3, 2023

      Triple-negative Breast Cancer Trial in Shanghai (A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, B1: TROP2 ADC)

      Not yet recruiting
      • Triple-negative Breast Cancer
      • A1: SHR-A1811
      • +11 more
      • Shanghai, China
        Fudan University Shanghai Cancer Center
      Feb 19, 2023

      Diabete Type 2, Obesity Trial in Orlando (HU6)

      Not yet recruiting
      • Diabete Type 2
      • Obesity
      • Orlando, Florida
        AdventHealth Translational Research Institute
      Oct 23, 2023

      Natural History Study for Charcot Marie Tooth Disease

      Recruiting
      • Charcot-Marie-Tooth Disease
      • +47 more
        • New York, New York
          Hereditary Neuropathy Foundation
        Jun 12, 2023

        Blood Metabolic Markers in Type 2 Diabetes Mellitus of Different

        Not yet recruiting
        • Diabetes Mellitus, Type 2
        • No intervention
        • Jinan, Shandong, China
          Peng Wu
        Nov 24, 2023

        HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

        Not yet recruiting
        • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
        • SHR-A1811
        • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
        • (no location specified)
        Nov 6, 2023

        Healthy Trial in Glendale (Y-2 Sublingual Tablet, Placebo)

        Not yet recruiting
        • Healthy
        • Y-2 Sublingual Tablet
        • Placebo
        • Glendale, California
          Parexel International Los Angeles Early Phase Clinical Unit
        Jul 10, 2023

        Advanced Solid Tumor, CDKN2A, NSCLC Trial (Milademetan, Atezolizumab)

        Withdrawn
        • Advanced Solid Tumor
        • +9 more
        • (no location specified)
        Oct 16, 2023

        Long-Term Development of Muscular Dystrophy Outcome Assessments

        Not yet recruiting
        • LGMD1A
        • +33 more
          • Richmond, Virginia
            Virginia Commonwealth University
          Aug 3, 2023

          COVID-19 Vaccine, COVID-19 Trial in Bangkok (50 µg Baiya SARS-CoV-2 Vax 2, Placebo)

          Not yet recruiting
          • COVID-19 Vaccine
          • COVID-19
          • 50 μg Baiya SARS-CoV-2 Vax 2
          • Placebo
          • Bangkok, Thailand
            Queen Saovabha Memorial Institute
          May 23, 2023

          Subcutaneous Fat Trial in Omaha (CBL-514 injection, CBL-A1 Injection, CBL-A2 Injection)

          Not yet recruiting
          • Subcutaneous Fat
          • CBL-514 injection
          • +3 more
          • Omaha, Nebraska
            Investigational Site 1
          Aug 17, 2023

          Type2diabetes, Obesity, Diet, Healthy Trial in Milano (Vegetarian Meal)

          Recruiting
          • Type2diabetes
          • +3 more
          • Vegetarian Meal
          • Milano, Italy
            IRCCS Ospedale San Raffaele
          Nov 28, 2023

          Tobacco Use Disorder, Diabetes, Type 2 Trial in Sevilla (Control group (waiting list), Cognitive Behavioral Treatment (CBT) for

          Not yet recruiting
          • Tobacco Use Disorder
          • Diabetes Mellitus, Type 2
          • Control group (waiting list)
          • +2 more
          • Sevilla, Spain
            Carla López Núñez
          May 22, 2023

          Healthy Participants Trial (mPnC candidate, mPnC control)

          Not yet recruiting
          • Healthy Participants
          • mPnC candidate
          • mPnC control
          • (no location specified)
          Oct 30, 2023

          Chronic Hepatitis B Trial run by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (VIR-2218 and

          Not yet recruiting
          • Chronic Hepatitis B
          • VIR-2218 and peginterferon alfa-2a
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          Oct 27, 2023

          Parent-Child Relations, Parenting Trial in Stockholm (ABC 0-2 years, waiting list)

          Completed
          • Parent-Child Relations
          • Parenting
          • ABC 0-2 years
          • waiting list
          • Stockholm, Sweden
            PLUS
          Sep 7, 2023